Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05775549 · ClinicalTrials.gov registry record
A Study to Characterize the Outcomes of Olaparib Maintenance Monotherapy in Newly Diagnosed BRCAwt Ovarian Cancer
A clinical trial, sponsored by AstraZeneca.
- Completed
- Registry status
- 24
- Enrollment target
NCT05775549 is a clinical trial that has completed, run by AstraZeneca. The registered enrollment target is 24 participants.
The verdict
NCT05775549 has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- 24 participants
- Enrollment target
Study Summary
This study will collect the data from existing patient medical records at US cancer centers. The study will include patients with BRCAwt ovarian cancer who have been prescribed first line (1L) olaparib maintenance treatment.
Interventions
- OTHER None (Observational Study)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2023-07-10 |
| Est. Completion | 2023-10-27 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05775549
The ClinicalTrials.gov registry entry for NCT05775549 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which None (Observational Study) is the first listed.
NCT05775549 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05775549 about?
NCT05775549 is a clinical study titled "A Study to Characterize the Outcomes of Olaparib Maintenance Monotherapy in Newly Diagnosed BRCAwt Ovarian Cancer". This study will collect the data from existing patient medical records at US cancer centers. The study will include patients with BRCAwt ovarian cancer who have been prescribed first line (1L) olaparib maintenance treatment.
What is the current status of trial NCT05775549?
This trial is currently completed. The enrollment target is 24 participants. The study started on 2023-07-10. Estimated completion is 2023-10-27.
What interventions are being tested in trial NCT05775549?
The interventions under investigation include: None (Observational Study) (OTHER).
Who is sponsoring clinical trial NCT05775549?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.